Neurogene Reports $29.0 Million Third-Quarter Net Loss
Neurogene reported a $29.0 million net loss for the third quarter of 2026, versus $21.0 million a year earlier. Cash, cash equivalents and short-term investments totaled $359.7 million at quarter-end; the headline says cash runway extends into Q1 2029.
Neurogene reported a net loss of $29.0 million for the third quarter of 2026, compared with $21.0 million a year earlier. Research and development expenses were $23.5 million, while cash, cash equivalents and short-term investments totaled $359.7 million at quarter-end. The company expects its cash…